Barry Jones
Overview
Explore the profile of Barry Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
756
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fandozzi C, Evans C, Wilson A, Anderson M, Clausen V, Dillen L, et al.
Bioanalysis
. 2019 Dec;
11(22):2029-2048.
PMID: 31808716
The 2019 13 Workshop on Recent Issues in Bioanalysis (WRIB) took place in New Orleans, LA, USA on April 1-5, 2019 with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical...
12.
Jang K, Otieno M, Ronxhi J, Lim H, Ewart L, Kodella K, et al.
Sci Transl Med
. 2019 Nov;
11(517).
PMID: 31694927
Nonclinical rodent and nonrodent toxicity models used to support clinical trials of candidate drugs may produce discordant results or fail to predict complications in humans, contributing to drug failures in...
13.
Menon S, Jones B
Aliment Pharmacol Ther
. 2019 Jun;
50(1):109.
PMID: 31184394
No abstract available.
14.
Welink J, Xu Y, Yang E, Wilson A, Henderson N, Luo L, et al.
Bioanalysis
. 2018 Nov;
10(22):1781-1801.
PMID: 30488725
The 2018 12 Workshop on Recent Issues in Bioanalysis (12th WRIB) took place in Philadelphia, PA, USA on April 9-13, 2018 with an attendance of over 900 representatives from pharmaceutical/biopharmaceutical...
15.
Bapiro T, Sykes A, Martin S, Davies M, Yates J, Hoch M, et al.
Drug Metab Dispos
. 2018 Jun;
46(9):1268-1276.
PMID: 29921707
AZD9496 ((E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid) is an oral selective estrogen receptor degrader currently in clinical development for treatment of estrogen receptor-positive breast cancer. In a first-in-human phase 1 study, AZD9496 exhibited dose...
16.
Solanki M, Pointon A, Jones B, Herbert K
Drug Metab Dispos
. 2018 Apr;
46(8):1053-1065.
PMID: 29695613
Drug-induced cardiotoxicity may be modulated by endogenous arachidonic acid (AA)-derived metabolites known as epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 2J2 (CYP2J2). The biologic effects of EETs, including their protective...
17.
Welink J, Yang E, Hughes N, Rago B, Woolf E, Sydor J, et al.
Bioanalysis
. 2017 Nov;
9(22):1807-1825.
PMID: 29148835
The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California from 3 April 2017 to 7 April 2017 with participation of close...
18.
Hariparsad N, Ramsden D, Palamanda J, DeKeyser J, Fahmi O, Kenny J, et al.
Drug Metab Dispos
. 2017 Jun;
45(10):1049-1059.
PMID: 28646080
The European Medicines Agency (EMA), the Pharmaceutical and Medical Devices Agency (PMDA), and the Food and Drug Administration (FDA) have issued guidelines for the conduct of drug-drug interaction studies. To...
19.
Jiang H, Titsch C, Zeng J, Jones B, Joyce P, Gandhi Y, et al.
J Pharm Biomed Anal
. 2017 May;
143:9-16.
PMID: 28544885
The oral absolute bioavailability of beclabuvir in healthy subjects was determined using a microdose (100μg) of the stable isotopically labeled tracer via intravenous (IV) infusion started after oral dosing of...
20.
Song A, Lee A, Garofolo F, Kaur S, Duggan J, Evans C, et al.
Bioanalysis
. 2016 Nov;
8(23):2457-2474.
PMID: 27855509
The 2016 10th Workshop on Recent Issues in Bioanalysis (10 WRIB) took place in Orlando, Florida with participation of close to 700 professionals from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research...